Болезнь-модифицирующая терапия псориаза в детском возрасте

Прогресс в понимании механизмов, лежащих в основе хронических воспалительных заболеваний кожи, таких как вульгарный псориаз, привел к появлению новых вариантов лечения, основной целью которых является облегчение симптомов. Кроме того, эти знания могут стать основой для новых стратегий достижения глубокой ремиссии или ремиссии без лечения, то есть модификации заболевания с потенциальным влиянием на сопутствующие состояния. Однако достижение этой цели требует дальнейшего изучения таких важных аспектов, как определение модификации заболевания и показателей активности болезни, дальнейшее понимание механизмов патогенеза, этиологии и системных побочных эффектов, окон потенциальных возможностей, биомаркеров для успешной стратификации пациентов и вмешательства, а также соответствующего дизайна исследования. Раннее вмешательство с использованием генно-инженерных биологических препаратов, таких как секукинумаб, представляет собой новый сдвиг парадигмы для улучшения результатов при иммуноопосредованных заболеваниях, необходимы доказательства для определения его полезности при псориазе. Высокий уровень устойчивого очищения кожи, наблюдаемый на фоне применения секукинумаба по сравнению со стандартным лечением и применением фототерапии, свидетельствует о потенциальной пользе раннего лечения биологическими препаратами для достижения полного очищения кожи и нормализации качества жизни, обучения и повседневной активности. Также это может служить обоснованием для изменения стратегии лечения пациентов с впервые выявленным умеренно тяжелым бляшечным псориазом. Ключевые слова: псориаз, дети, секукинумаб, болезнь-модифицирующая терапия.

1. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. doi: https://doi.org/10.1038/jid.2013.446

2. Braun-Falco’s Dermatology. Plewig G, French LE, Ruzicka T, et al., eds. Heidelberg: Springer Berlin; 2022.

3. Boch K, Langan EA, Kridin K, et al. Lichen planus. Front Med (Lausanne). 2021;8:737813. doi: https://doi.org/10.3389/fmed.2021.737813

4. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. doi: https://doi.org/10.1038/s41572-022-00389-z

5. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819–1831. doi: https://doi.org/10.1016/j.jaci.2022.04.010

6. Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. doi: https://doi.org/10.1038/s41572-020-0149-1

7. Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102–113. doi: https://doi.org/10.1007/s12016-018-8668-1

8. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi: https://doi.org/10.1016/S0140-6736(20)32549-6

9. Kara T, Topkarcı Z, Yılmaz S, et al. Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a casecontrol study. J Dermatol Treat. 2019;30(2):129–134. doi: https://doi.org/10.1080/09546634.2018.1476653

10. Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children (Basel). 2021;8(11):1057. doi: https://doi.org/10.3390/children8111057

11. Datta D, Sarkar R, Podder I. Parental stress and quality of life in chronic childhood dermatoses: a review. J Clin Aesthet Dermatol. 2021;14(9 Suppl 1):S19–S23.

12. Mendonca JA, Aydin SZ, D’Agostino MA. The use of ultrasonography in the diagnosis of nail disease among patients with psoriasis and psoriatic arthritis: a systematic review. Adv Rheumatol. 2019;59(1):41. doi: https://doi.org/10.1186/s42358-019-0081-9

13. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. doi: https://doi.org/10.3389/fphar.2020.00117

14. van de Kerkhof PC. Biologics for psoriasis: maintenance treatment and true disease modification. J Dermatol Treat. 2017;28(4):281. doi: https://doi.org/10.1080/09546634.2017.1336829

15. Crowl JT, Heeg M, Ferry A, et al. Tissue-resident memory CD8(+) T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments. Nat Immunol. 2022;23(7): 1121–1131. doi: https://doi.org/10.1038/s41590-022-01229-8

16. Suárez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol. 2011;131(2):391–400. doi: https://doi.org/10.1038/jid.2010.280

17. Matos TR, O’Malley JT, Lowry EL, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest. 2017;127(11):4031–4041. doi: https://doi.org/10.1172/JCI93396

18. Gallais Sérézal I, Hoffer E, Ignatov B, et al. A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis. J Allergy Clin Immunol. 2019;143(4):1444–1454. doi: https://doi.org/10.1016/j.jaci.2018.08.048

19. Martini E, Wikén M, Cheuk S, et al. Dynamic Changes in Resident and Infiltrating Epidermal Dendritic Cells in Active and Resolved Psoriasis. J Invest Dermatol. 2017;137(4):865–873. doi: https://doi.org/10.1016/j.jid.2016.11.033

20. Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis. J Immunol. 2014;192(7):3111–3120. doi: https://doi.org/10.4049/jimmunol.1302313

21. Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification — rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32(11):1930–1939. doi: https://doi.org/10.1111/jdv.14979

22. Mahler V, Mentzer D, Bonertz A, et al. Allergen immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation — summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-EhrlichInstitut, Langen, Germany, 16.1.2019. Clin Transl Allergy. 2020;10:28. doi: https://doi.org/10.1186/s13601-020-00327-w

23. Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8): 662–680. doi: https://doi.org/10.1038/s41573-023-00735-0

24. Luo Y, Qu K, Kuai L, et al. Epigenetics in psoriasis: perspective of DNA methylation. Mol Genet Genomics. 2021;296(5):1027–1040. doi: https://doi.org/10.1007/s00438-021-01804-y

25. Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130. doi: https://doi.org/10.1016/j.jaci.2018.11.038

26. Dand N, Mahil SK, Capon F, et al. Psoriasis and genetics. Acta Derm Venereol. 2020;100(3):adv00030. doi: https://doi.org/10.2340/00015555-3384

27. Schon MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323. doi: https://doi.org/10.3389/fimmu.2018.01323

28. Bridgewood C, Newton D, Bragazzi N, et al. Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis. Semin Immunol. 2021;58:101520. doi: https://doi.org/10.1016/j.smim.2021.101520

29. Bugaut H, Aractingi S. Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol. 2021;12:621956. doi: https://doi.org/10.3389/fimmu.2021.621956

30. Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chron Dis. 2021;12:20406223211037846. doi: https://doi.org/10.1177/20406223211037846

31. Ryan GE, Harris JE, Richmond JM. Resident memory T cells in autoimmune skin diseases. Front Immunol. 2021;12:652191. doi: https://doi.org/10.3389/fimmu.2021.652191

32. Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate — to severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–663. doi: https://doi.org/10.1111/bjd.20827

33. Conrad C, Boyman O, Tonel G, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med. 2007;13(7):836–842. doi: https://doi.org/10.1038/nm1605

34. Patrick MT, Stuart PE, Zhang H, et al. Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through transdisease meta-analysis. J Invest Dermatol. 2021;141(6):1493–1502. doi: https://doi.org/10.1016/j.jid.2020.11.025

35. van de Kerkhof PC. From empirical to pathogenesis-based treatments for psoriasis. J Invest Dermatol. 2022;142(7):1778–1785. doi: https://doi.org/10.1016/j.jid.2022.01.014

36. Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol. 2019;139(12):2437–2446.e1. doi: https://doi.org/10.1016/j.jid.2019.05.016

37. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493. doi: https://doi.org/10.1111/bjd.13348.

38. Golbari NM, van der Walt JM, Blauvelt A, et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35(2):417–421. doi: https://doi.org/10.1111/jdv.16966

39. Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatol Treat. 2020;31(8):769–775. doi: https://doi.org/10.1080/09546634.2019.1626973

40. Girolomoni G, Griffiths CE, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatol Treat. 2015;26(2):103–112. doi: https://doi.org/10.3109/09546634.2014.880396

41. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004; 43(7):906–914. doi: https://doi.org/10.1093/rheumatology/keh199

42. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–667. doi: https://doi.org/10.1016/S0140-6736(08)60304-9

43. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009;66(4):513–520. doi: https://doi.org/10.1002/ana.21757

44. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi: https://doi.org/10.1126/scitranslmed.3001107

45. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4): 326–338. doi: https://doi.org/10.1056/NEJMoa1314258

46. Ben Abdallah H, Emmanuel T, Bregnhøj A, et al. Early intervention and disease memory in psoriasis: a literature review. JEADV Clin Pract. 2022;1:307–316. doi: https://doi.org/10.1002/jvc2.63

47. Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35(2): 431–440. doi: https://doi.org/10.1111/jdv.16632

48. Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020;31(5):476–483. doi: https://doi.org/10.1080/09546634.2019.1671577

49. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9): 1507–1514. doi: https://doi.org/10.1111/jdv.14878

50. Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: review of practical guidelines. Am J Clin Dermatol. 2016;17(2):125–133. doi: https://doi.org/10.1007/s40257-016-0176-6

51. Kerdel F, Don F. The importance of early treatment in psoriasis and management of disease progression. J Drugs Dermatol. 2018;17(7):737–742.